- Home
- CELC vs MEOH Comparison
CELC vs MEOH Comparison
Compare CELC & MEOH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- MEOH
- Stock Information
- Founded
- CELC 2011
- MEOH 1968
- Country
- CELC United States
- MEOH Canada
- Employees
- CELC N/A
- MEOH N/A
- Industry
- CELC Medical Specialities
- MEOH Major Chemicals
- Sector
- CELC Health Care
- MEOH Industrials
- Exchange
- CELC Nasdaq
- MEOH Nasdaq
- Market Cap
- CELC 3.1B
- MEOH 2.9B
- IPO Year
- CELC 2017
- MEOH N/A
- Fundamental
- Price
- CELC $74.11
- MEOH $36.08
- Analyst Decision
- CELC Strong Buy
- MEOH Buy
- Analyst Count
- CELC 5
- MEOH 9
- Target Price
- CELC $69.40
- MEOH $47.22
- AVG Volume (30 Days)
- CELC 1.4M
- MEOH 590.1K
- Earning Date
- CELC 11-12-2025
- MEOH 10-29-2025
- Dividend Yield
- CELC N/A
- MEOH 2.06%
- EPS Growth
- CELC N/A
- MEOH 40.35
- EPS
- CELC N/A
- MEOH 2.98
- Revenue
- CELC N/A
- MEOH $3,569,374,000.00
- Revenue This Year
- CELC N/A
- MEOH $2.07
- Revenue Next Year
- CELC N/A
- MEOH $12.69
- P/E Ratio
- CELC N/A
- MEOH $12.08
- Revenue Growth
- CELC N/A
- MEOH N/A
- 52 Week Low
- CELC $7.58
- MEOH $25.46
- 52 Week High
- CELC $83.00
- MEOH $54.49
- Technical
- Relative Strength Index (RSI)
- CELC 64.02
- MEOH 49.55
- Support Level
- CELC $71.06
- MEOH $35.67
- Resistance Level
- CELC $79.97
- MEOH $39.81
- Average True Range (ATR)
- CELC 5.13
- MEOH 1.60
- MACD
- CELC 0.11
- MEOH 0.20
- Stochastic Oscillator
- CELC 53.43
- MEOH 53.01
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About MEOH Methanex Corporation
Methanex Corp manufactures and sells methanol. Its customers use methanol as a feedstock to produce end-products including adhesives, foams, solvents, and windshield washer fluids. The firm also sells its products to the oil refining industry, where the methanol is blended with gasoline to produce a high-octane fuel or blended as a component of biodiesel. It distributes its products through an extensive supply chain that includes the operation of port terminals, tankers, barges, rail cars, trucks, and pipelines. The company generates the majority of its revenue from Europe.